CStone Pharmaceuticals has announced that it will present new clinical advancements at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany, which is scheduled to take place from October 17-21. Key presentations will include the first-in-human Phase Ia data for the novel PD-1/VEGF/CTLA-4 trispecific antibody, CS2009, as well as the design of a global multicenter Phase Ib study for its ROR1-targeting antibody-drug conjugate $(ADC)$, CS5001. These presentations aim to showcase the latest developments from CStone's Pipeline 2.0. The company advises that the forward-looking statements made in the announcement are subject to change based on future developments.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。